Atopic Dermatitis

Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.

Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.

Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.

Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027

Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.

Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.

Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.

Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027

Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.

Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.

Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.

Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027

Key clinical point: Children diagnosed with atopic dermatitis (AD) within the first 10 years of life are more likely to develop a more proinflammatory dietary pattern and consume less fiber and several vitamins, which may worsen the atopic outcome itself.

Major finding: The intake of fiber (P = .04), vitamin C (P = .02), vitamin E (P = .03), and vitamin B₇ (biotin) (P = .047) were significantly lower among children who developed vs did not develop AD in the first 10 years of life, with a significant association observed between presence of AD and a proinflammatory dietary pattern at 10 years of age (odds ratio 2.22; P = .02).

Study details: Findings are from the population-based LiNA cohort study including 211 10-year-old children.

Disclosures: This LiNA study was funded by the Department of Environmental Immunology, Helmholtz Centre for Environmental Research. JR Hebert declared owning controlling interest in Connecting Health Innovations LLC.

Source: Schütte O et al. Pro-inflammatory diet pictured in children with atopic dermatitis or food allergy: Nutritional data of the LiNA cohort. Front Nutr. 2022;9:868872 (Apr 8). Doi: 10.3389/fnut.2022.868872

Key clinical point: Children diagnosed with atopic dermatitis (AD) within the first 10 years of life are more likely to develop a more proinflammatory dietary pattern and consume less fiber and several vitamins, which may worsen the atopic outcome itself.

Major finding: The intake of fiber (P = .04), vitamin C (P = .02), vitamin E (P = .03), and vitamin B₇ (biotin) (P = .047) were significantly lower among children who developed vs did not develop AD in the first 10 years of life, with a significant association observed between presence of AD and a proinflammatory dietary pattern at 10 years of age (odds ratio 2.22; P = .02).

Study details: Findings are from the population-based LiNA cohort study including 211 10-year-old children.

Disclosures: This LiNA study was funded by the Department of Environmental Immunology, Helmholtz Centre for Environmental Research. JR Hebert declared owning controlling interest in Connecting Health Innovations LLC.

Source: Schütte O et al. Pro-inflammatory diet pictured in children with atopic dermatitis or food allergy: Nutritional data of the LiNA cohort. Front Nutr. 2022;9:868872 (Apr 8). Doi: 10.3389/fnut.2022.868872

Key clinical point: Children diagnosed with atopic dermatitis (AD) within the first 10 years of life are more likely to develop a more proinflammatory dietary pattern and consume less fiber and several vitamins, which may worsen the atopic outcome itself.

Major finding: The intake of fiber (P = .04), vitamin C (P = .02), vitamin E (P = .03), and vitamin B₇ (biotin) (P = .047) were significantly lower among children who developed vs did not develop AD in the first 10 years of life, with a significant association observed between presence of AD and a proinflammatory dietary pattern at 10 years of age (odds ratio 2.22; P = .02).

Study details: Findings are from the population-based LiNA cohort study including 211 10-year-old children.

Disclosures: This LiNA study was funded by the Department of Environmental Immunology, Helmholtz Centre for Environmental Research. JR Hebert declared owning controlling interest in Connecting Health Innovations LLC.

Source: Schütte O et al. Pro-inflammatory diet pictured in children with atopic dermatitis or food allergy: Nutritional data of the LiNA cohort. Front Nutr. 2022;9:868872 (Apr 8). Doi: 10.3389/fnut.2022.868872

Key clinical point: Antioxidants show favorable efficacy and safety as an adjunct therapy for atopic dermatitis (AD), particularly when supplemented with oral vitamin D and topical vitamin B₁₂.

Major finding: Overall, antioxidants vs placebo were associated with a significant reduction in disease severity scores (P < .0001), with a significant decrease in AD severity observed for oral supplementation with vitamin D (P = .01); combined vitamins D and E (P = .003); combined vitamins A, D, and E (P = .02); and topical vitamin B₁₂ (P < .0001). No serious adverse events were reported.

Study details: Findings are from a meta-analysis of 18 studies including 763 patients with AD.

Disclosures: This study did not receive any funding. No conflict of interests was reported.

Source: Yang H et al. Efficacy and safety profile of antioxidants in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Dermatol Ther. 2022 (May 3). Doi: 10.1111/dth.15549

Key clinical point: Antioxidants show favorable efficacy and safety as an adjunct therapy for atopic dermatitis (AD), particularly when supplemented with oral vitamin D and topical vitamin B₁₂.

Major finding: Overall, antioxidants vs placebo were associated with a significant reduction in disease severity scores (P < .0001), with a significant decrease in AD severity observed for oral supplementation with vitamin D (P = .01); combined vitamins D and E (P = .003); combined vitamins A, D, and E (P = .02); and topical vitamin B₁₂ (P < .0001). No serious adverse events were reported.

Study details: Findings are from a meta-analysis of 18 studies including 763 patients with AD.

Disclosures: This study did not receive any funding. No conflict of interests was reported.

Source: Yang H et al. Efficacy and safety profile of antioxidants in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Dermatol Ther. 2022 (May 3). Doi: 10.1111/dth.15549

Key clinical point: Antioxidants show favorable efficacy and safety as an adjunct therapy for atopic dermatitis (AD), particularly when supplemented with oral vitamin D and topical vitamin B₁₂.

Major finding: Overall, antioxidants vs placebo were associated with a significant reduction in disease severity scores (P < .0001), with a significant decrease in AD severity observed for oral supplementation with vitamin D (P = .01); combined vitamins D and E (P = .003); combined vitamins A, D, and E (P = .02); and topical vitamin B₁₂ (P < .0001). No serious adverse events were reported.

Study details: Findings are from a meta-analysis of 18 studies including 763 patients with AD.

Disclosures: This study did not receive any funding. No conflict of interests was reported.

Source: Yang H et al. Efficacy and safety profile of antioxidants in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Dermatol Ther. 2022 (May 3). Doi: 10.1111/dth.15549

Key clinical point: Dupilumab improved clinical scores in a real-world population of adolescents with moderate-to-severe atopic dermatitis (AD) and had a tolerable safety profile.

Major finding: After 16 weeks, the mean Eczema Area and Severity Index (EASI) score and Children Dermatology Life Quality Index and Numeric Rating Scale sleep loss scores reduced significantly by 79.8%, 72.9%, and 75.8%, respectively (all P < .01), with a higher proportion of patients with diffuse eczema vs. other clinical phenotypes reporting ≥90% and 100% improvement in EASI scores (P < .05). Adverse events (AE) were reported by 20.1% of adolescents, but none discontinued dupilumab because of AE.

Study details: This prospective study included 139 adolescents aged ≥12 to <18 years with moderate-to-severe AD who received dupilumab for 16 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as principal investigators, advisory board members, speakers, or consultants, or receiving personal fees, consulting fees, or payments or honoraria from several sources.

Source: Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022 (Apr 12). Doi: 10.1111/jdv.18141

Key clinical point: Dupilumab improved clinical scores in a real-world population of adolescents with moderate-to-severe atopic dermatitis (AD) and had a tolerable safety profile.

Major finding: After 16 weeks, the mean Eczema Area and Severity Index (EASI) score and Children Dermatology Life Quality Index and Numeric Rating Scale sleep loss scores reduced significantly by 79.8%, 72.9%, and 75.8%, respectively (all P < .01), with a higher proportion of patients with diffuse eczema vs. other clinical phenotypes reporting ≥90% and 100% improvement in EASI scores (P < .05). Adverse events (AE) were reported by 20.1% of adolescents, but none discontinued dupilumab because of AE.

Study details: This prospective study included 139 adolescents aged ≥12 to <18 years with moderate-to-severe AD who received dupilumab for 16 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as principal investigators, advisory board members, speakers, or consultants, or receiving personal fees, consulting fees, or payments or honoraria from several sources.

Source: Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022 (Apr 12). Doi: 10.1111/jdv.18141

Key clinical point: Dupilumab improved clinical scores in a real-world population of adolescents with moderate-to-severe atopic dermatitis (AD) and had a tolerable safety profile.

Major finding: After 16 weeks, the mean Eczema Area and Severity Index (EASI) score and Children Dermatology Life Quality Index and Numeric Rating Scale sleep loss scores reduced significantly by 79.8%, 72.9%, and 75.8%, respectively (all P < .01), with a higher proportion of patients with diffuse eczema vs. other clinical phenotypes reporting ≥90% and 100% improvement in EASI scores (P < .05). Adverse events (AE) were reported by 20.1% of adolescents, but none discontinued dupilumab because of AE.

Study details: This prospective study included 139 adolescents aged ≥12 to <18 years with moderate-to-severe AD who received dupilumab for 16 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as principal investigators, advisory board members, speakers, or consultants, or receiving personal fees, consulting fees, or payments or honoraria from several sources.

Source: Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022 (Apr 12). Doi: 10.1111/jdv.18141

Key clinical point: Nemolizumab was safe and more effective than placebo in reducing the severity of atopic dermatitis (AD) or pruritus.

Major finding: Nemolizumab vs placebo significantly reduced the pruritus visual analogue scale score (weighted mean difference [WMD] −18.86; P < .001) and Eczema Area and Severity Index score (WMD −11.76; P = .009). Adverse events were mostly mild and similar in both the groups (P = .593).

Study details: This was a meta-analysis of 14 cohorts of participants from six randomized controlled studies that included 569 and 240 patients with AD or pruritus who received nemolizumab and placebo, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Liang J et al. Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. 2022;13:825312 (Apr 26). Doi: 10.3389/fimmu.2022.825312

Key clinical point: Nemolizumab was safe and more effective than placebo in reducing the severity of atopic dermatitis (AD) or pruritus.

Major finding: Nemolizumab vs placebo significantly reduced the pruritus visual analogue scale score (weighted mean difference [WMD] −18.86; P < .001) and Eczema Area and Severity Index score (WMD −11.76; P = .009). Adverse events were mostly mild and similar in both the groups (P = .593).

Study details: This was a meta-analysis of 14 cohorts of participants from six randomized controlled studies that included 569 and 240 patients with AD or pruritus who received nemolizumab and placebo, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Liang J et al. Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. 2022;13:825312 (Apr 26). Doi: 10.3389/fimmu.2022.825312

Key clinical point: Nemolizumab was safe and more effective than placebo in reducing the severity of atopic dermatitis (AD) or pruritus.

Major finding: Nemolizumab vs placebo significantly reduced the pruritus visual analogue scale score (weighted mean difference [WMD] −18.86; P < .001) and Eczema Area and Severity Index score (WMD −11.76; P = .009). Adverse events were mostly mild and similar in both the groups (P = .593).

Study details: This was a meta-analysis of 14 cohorts of participants from six randomized controlled studies that included 569 and 240 patients with AD or pruritus who received nemolizumab and placebo, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Liang J et al. Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. 2022;13:825312 (Apr 26). Doi: 10.3389/fimmu.2022.825312

Key clinical point: Children with atopic dermatitis (AD) may have a higher sensitivity to contact allergens, such as fragrances and metals, than children without AD.

Major finding: Overall, 36.9% vs 26.4% of children with vs without AD presented with at least one positive patch test. Children with v. without AD showed a higher prevalence of ≥1 positive patch test for allergens, such as nickel sulfate, cobalt chloride, methylisothiazolinone, fragrance mix-2, potassium dichromate, fragrance mix-1, methylchloroisothiazolinone/methylisothiazolinone, and neomycin sulfate, with the prevalence difference being highest for fragrance mix-1 (5.8% vs 0.9%; P = .004293).

Study details: This retrospective study included 432 children aged 0-14 years with eczematous dermatitis who underwent patch testing, of which 23.8% of children were diagnosed with AD.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Bonamonte D et al. Contact allergy in children with and without atopic dermatitis: An Italian multicentre study. Contact Dermatitis. 2022 (Apr 21). Doi: 10.1111/cod.14130

Key clinical point: Children with atopic dermatitis (AD) may have a higher sensitivity to contact allergens, such as fragrances and metals, than children without AD.

Major finding: Overall, 36.9% vs 26.4% of children with vs without AD presented with at least one positive patch test. Children with v. without AD showed a higher prevalence of ≥1 positive patch test for allergens, such as nickel sulfate, cobalt chloride, methylisothiazolinone, fragrance mix-2, potassium dichromate, fragrance mix-1, methylchloroisothiazolinone/methylisothiazolinone, and neomycin sulfate, with the prevalence difference being highest for fragrance mix-1 (5.8% vs 0.9%; P = .004293).

Study details: This retrospective study included 432 children aged 0-14 years with eczematous dermatitis who underwent patch testing, of which 23.8% of children were diagnosed with AD.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Bonamonte D et al. Contact allergy in children with and without atopic dermatitis: An Italian multicentre study. Contact Dermatitis. 2022 (Apr 21). Doi: 10.1111/cod.14130

Key clinical point: Children with atopic dermatitis (AD) may have a higher sensitivity to contact allergens, such as fragrances and metals, than children without AD.

Major finding: Overall, 36.9% vs 26.4% of children with vs without AD presented with at least one positive patch test. Children with v. without AD showed a higher prevalence of ≥1 positive patch test for allergens, such as nickel sulfate, cobalt chloride, methylisothiazolinone, fragrance mix-2, potassium dichromate, fragrance mix-1, methylchloroisothiazolinone/methylisothiazolinone, and neomycin sulfate, with the prevalence difference being highest for fragrance mix-1 (5.8% vs 0.9%; P = .004293).

Study details: This retrospective study included 432 children aged 0-14 years with eczematous dermatitis who underwent patch testing, of which 23.8% of children were diagnosed with AD.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Bonamonte D et al. Contact allergy in children with and without atopic dermatitis: An Italian multicentre study. Contact Dermatitis. 2022 (Apr 21). Doi: 10.1111/cod.14130

Key clinical point: Dupilumab showed an acceptable safety profile and sustained efficacy through 4 years in adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At 4 years, the exposure-adjusted incidence rate of treatment emergent adverse events (TEAE) was 256.86 events/100 patient-years, with most events being mild to moderate in severity. At least one serious and severe TEAE was experienced by 10.4% and 9.8% of patients in two dose categories. At week 204, the mean Eczema Area and Severity Index (EASI) score improved by 91.07%, with patients switching from 300 mg dupilumab weekly to every-2-weeks dosing while maintaining EASI scores up to 48 weeks post-transition.

Study details: Findings are from an interim analysis of the ongoing phase 3, LIBERTY AD open-label extension study including 2677 adults with moderate-to-severe AD who received 300 mg dupilumab  weekly or every 2 weeks in previous phase 1-3 AD trials.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Seven authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi, and other authors reported ties with various sources.

Source: Beck LA et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022 (May 3). Doi: 10.1007/s40257-022-00685-0

Key clinical point: Dupilumab showed an acceptable safety profile and sustained efficacy through 4 years in adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At 4 years, the exposure-adjusted incidence rate of treatment emergent adverse events (TEAE) was 256.86 events/100 patient-years, with most events being mild to moderate in severity. At least one serious and severe TEAE was experienced by 10.4% and 9.8% of patients in two dose categories. At week 204, the mean Eczema Area and Severity Index (EASI) score improved by 91.07%, with patients switching from 300 mg dupilumab weekly to every-2-weeks dosing while maintaining EASI scores up to 48 weeks post-transition.

Study details: Findings are from an interim analysis of the ongoing phase 3, LIBERTY AD open-label extension study including 2677 adults with moderate-to-severe AD who received 300 mg dupilumab  weekly or every 2 weeks in previous phase 1-3 AD trials.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Seven authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi, and other authors reported ties with various sources.

Source: Beck LA et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022 (May 3). Doi: 10.1007/s40257-022-00685-0

Key clinical point: Dupilumab showed an acceptable safety profile and sustained efficacy through 4 years in adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At 4 years, the exposure-adjusted incidence rate of treatment emergent adverse events (TEAE) was 256.86 events/100 patient-years, with most events being mild to moderate in severity. At least one serious and severe TEAE was experienced by 10.4% and 9.8% of patients in two dose categories. At week 204, the mean Eczema Area and Severity Index (EASI) score improved by 91.07%, with patients switching from 300 mg dupilumab weekly to every-2-weeks dosing while maintaining EASI scores up to 48 weeks post-transition.

Study details: Findings are from an interim analysis of the ongoing phase 3, LIBERTY AD open-label extension study including 2677 adults with moderate-to-severe AD who received 300 mg dupilumab  weekly or every 2 weeks in previous phase 1-3 AD trials.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Seven authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi, and other authors reported ties with various sources.

Source: Beck LA et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022 (May 3). Doi: 10.1007/s40257-022-00685-0

Key clinical point: Baricitinib plus topical corticosteroids (TCS) improved the signs and symptoms of atopic dermatitis (AD) through 1 year along with a consistent safety profile in patients with moderate-to-severe AD and an inadequate response, intolerance, or contraindication to cyclosporine A (CyA).

Major finding: At week 16, ≥75% improvement in the Eczema Area and Severity Index was achieved by a significantly higher proportion of patients receiving 4 mg baricitinib+TCS vs placebo+TCS (32% vs 17%; P = .031), with improvements maintained through week 52. Treatment emergent adverse events were more frequent with baricitinib, but were mostly mild or moderate in severity.

Study details: Findings are from the phase 3 BREEZE-AD4 study including 463 patients with moderate-to-severe AD and an inadequate response, contraindication, or intolerance to CyA who were randomly assigned to receive placebo+TCS or 1, 2, or 4 mg baricitinib+TCS for 52 weeks.

Disclosures: Eli Lilly and Company developed baricitinib. Six authors declared being employees and shareholders of Eli Lilly, and other authors reported ties with various sources, including Eli Lilly.

Source: Bieber T et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance, or contraindication to cyclosporine: Results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022 (Apr 28). Doi: 10.1111/bjd.21630

Key clinical point: Baricitinib plus topical corticosteroids (TCS) improved the signs and symptoms of atopic dermatitis (AD) through 1 year along with a consistent safety profile in patients with moderate-to-severe AD and an inadequate response, intolerance, or contraindication to cyclosporine A (CyA).

Major finding: At week 16, ≥75% improvement in the Eczema Area and Severity Index was achieved by a significantly higher proportion of patients receiving 4 mg baricitinib+TCS vs placebo+TCS (32% vs 17%; P = .031), with improvements maintained through week 52. Treatment emergent adverse events were more frequent with baricitinib, but were mostly mild or moderate in severity.

Study details: Findings are from the phase 3 BREEZE-AD4 study including 463 patients with moderate-to-severe AD and an inadequate response, contraindication, or intolerance to CyA who were randomly assigned to receive placebo+TCS or 1, 2, or 4 mg baricitinib+TCS for 52 weeks.

Disclosures: Eli Lilly and Company developed baricitinib. Six authors declared being employees and shareholders of Eli Lilly, and other authors reported ties with various sources, including Eli Lilly.

Source: Bieber T et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance, or contraindication to cyclosporine: Results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022 (Apr 28). Doi: 10.1111/bjd.21630

Key clinical point: Baricitinib plus topical corticosteroids (TCS) improved the signs and symptoms of atopic dermatitis (AD) through 1 year along with a consistent safety profile in patients with moderate-to-severe AD and an inadequate response, intolerance, or contraindication to cyclosporine A (CyA).

Major finding: At week 16, ≥75% improvement in the Eczema Area and Severity Index was achieved by a significantly higher proportion of patients receiving 4 mg baricitinib+TCS vs placebo+TCS (32% vs 17%; P = .031), with improvements maintained through week 52. Treatment emergent adverse events were more frequent with baricitinib, but were mostly mild or moderate in severity.

Study details: Findings are from the phase 3 BREEZE-AD4 study including 463 patients with moderate-to-severe AD and an inadequate response, contraindication, or intolerance to CyA who were randomly assigned to receive placebo+TCS or 1, 2, or 4 mg baricitinib+TCS for 52 weeks.

Disclosures: Eli Lilly and Company developed baricitinib. Six authors declared being employees and shareholders of Eli Lilly, and other authors reported ties with various sources, including Eli Lilly.

Source: Bieber T et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance, or contraindication to cyclosporine: Results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022 (Apr 28). Doi: 10.1111/bjd.21630

Key clinical point: A substantial proportion of patients with moderate-to-severe atopic dermatitis (AD) achieved a higher threshold efficacy response (90% to <100% improvement in the Eczema Area and Severity Index [EASI-90 to <EASI-100] and EASI-100) with abrocitinib, which subsequently improved their quality of life (QoL).

Major finding: At week 12, a higher proportion of patients receiving 200 mg and 100 mg abrocitinib vs. placebo achieved EASI-90 to <EASI-100 (29.3% and 15.9% vs 5.9%) and EASI-100 (10.7% and 6.0% vs 0%), of which 48.9% and 48.1% vs 33.3% of patients with EASI-90 to <EASI-100 and 67.6% and 63.2% vs 0% of patients with EASI-100 showed QoL benefits.

Study details: Findings are from a post hoc analysis of one phase 2b and two phase 3 (JADE Mono-1 and JADE Mono-2) studies including 942 patients with moderate-to-severe AD and an inadequate response to topical medications who received once-daily 200 mg abrocitinib, 100 mg abrocitinib, or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Four authors declared being employees and shareholders of Pfizer, and other authors reported ties with several sources, including Pfizer.

Source: Stander S et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022 (Apr 24). Doi: 10.1111/jdv.18170

Key clinical point: A substantial proportion of patients with moderate-to-severe atopic dermatitis (AD) achieved a higher threshold efficacy response (90% to <100% improvement in the Eczema Area and Severity Index [EASI-90 to <EASI-100] and EASI-100) with abrocitinib, which subsequently improved their quality of life (QoL).

Major finding: At week 12, a higher proportion of patients receiving 200 mg and 100 mg abrocitinib vs. placebo achieved EASI-90 to <EASI-100 (29.3% and 15.9% vs 5.9%) and EASI-100 (10.7% and 6.0% vs 0%), of which 48.9% and 48.1% vs 33.3% of patients with EASI-90 to <EASI-100 and 67.6% and 63.2% vs 0% of patients with EASI-100 showed QoL benefits.

Study details: Findings are from a post hoc analysis of one phase 2b and two phase 3 (JADE Mono-1 and JADE Mono-2) studies including 942 patients with moderate-to-severe AD and an inadequate response to topical medications who received once-daily 200 mg abrocitinib, 100 mg abrocitinib, or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Four authors declared being employees and shareholders of Pfizer, and other authors reported ties with several sources, including Pfizer.

Source: Stander S et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022 (Apr 24). Doi: 10.1111/jdv.18170

Key clinical point: A substantial proportion of patients with moderate-to-severe atopic dermatitis (AD) achieved a higher threshold efficacy response (90% to <100% improvement in the Eczema Area and Severity Index [EASI-90 to <EASI-100] and EASI-100) with abrocitinib, which subsequently improved their quality of life (QoL).

Major finding: At week 12, a higher proportion of patients receiving 200 mg and 100 mg abrocitinib vs. placebo achieved EASI-90 to <EASI-100 (29.3% and 15.9% vs 5.9%) and EASI-100 (10.7% and 6.0% vs 0%), of which 48.9% and 48.1% vs 33.3% of patients with EASI-90 to <EASI-100 and 67.6% and 63.2% vs 0% of patients with EASI-100 showed QoL benefits.

Study details: Findings are from a post hoc analysis of one phase 2b and two phase 3 (JADE Mono-1 and JADE Mono-2) studies including 942 patients with moderate-to-severe AD and an inadequate response to topical medications who received once-daily 200 mg abrocitinib, 100 mg abrocitinib, or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Four authors declared being employees and shareholders of Pfizer, and other authors reported ties with several sources, including Pfizer.

Source: Stander S et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022 (Apr 24). Doi: 10.1111/jdv.18170

Key clinical point: Abrocitinib can be considered a treatment option for patients with moderate-to-severe atopic dermatitis (AD) regardless of prior response to dupilumab.

Major finding: At 12 weeks, ≥75% improvement in the Eczema Area and Severity Index was achieved by 80.0% (95% CI 62.5%-97.5%) and 67.7% (95% CI 51.3%-84.2%) of prior dupilumab nonresponders and 93.5% (95% CI 86.3%-100.0%) and 90.2% (95% CI 84.1%-96.3%) of prior dupilumab responders who received 200 mg and 100 mg abrocitinib, respectively. The most common treatment emergent adverse events were nasopharyngitis, nausea, acne, and headache.

Study details: This phase 3 study, JADE EXTEND,  included 203 patients with moderate-to-severe AD who were randomly assigned to receive 200 mg or 100 mg abrocitinib once-daily after receiving dupilumab for 14 weeks in JADE COMPARE.

Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees or shareholders of Pfizer and other authors reported ties with various sources, including Pfizer.

Source: Shi VY et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022 (Apr 16). Doi: 10.1016/j.jaad.2022.04.009

Key clinical point: Abrocitinib can be considered a treatment option for patients with moderate-to-severe atopic dermatitis (AD) regardless of prior response to dupilumab.

Major finding: At 12 weeks, ≥75% improvement in the Eczema Area and Severity Index was achieved by 80.0% (95% CI 62.5%-97.5%) and 67.7% (95% CI 51.3%-84.2%) of prior dupilumab nonresponders and 93.5% (95% CI 86.3%-100.0%) and 90.2% (95% CI 84.1%-96.3%) of prior dupilumab responders who received 200 mg and 100 mg abrocitinib, respectively. The most common treatment emergent adverse events were nasopharyngitis, nausea, acne, and headache.

Study details: This phase 3 study, JADE EXTEND,  included 203 patients with moderate-to-severe AD who were randomly assigned to receive 200 mg or 100 mg abrocitinib once-daily after receiving dupilumab for 14 weeks in JADE COMPARE.

Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees or shareholders of Pfizer and other authors reported ties with various sources, including Pfizer.

Source: Shi VY et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022 (Apr 16). Doi: 10.1016/j.jaad.2022.04.009

Key clinical point: Abrocitinib can be considered a treatment option for patients with moderate-to-severe atopic dermatitis (AD) regardless of prior response to dupilumab.

Major finding: At 12 weeks, ≥75% improvement in the Eczema Area and Severity Index was achieved by 80.0% (95% CI 62.5%-97.5%) and 67.7% (95% CI 51.3%-84.2%) of prior dupilumab nonresponders and 93.5% (95% CI 86.3%-100.0%) and 90.2% (95% CI 84.1%-96.3%) of prior dupilumab responders who received 200 mg and 100 mg abrocitinib, respectively. The most common treatment emergent adverse events were nasopharyngitis, nausea, acne, and headache.

Study details: This phase 3 study, JADE EXTEND,  included 203 patients with moderate-to-severe AD who were randomly assigned to receive 200 mg or 100 mg abrocitinib once-daily after receiving dupilumab for 14 weeks in JADE COMPARE.

Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees or shareholders of Pfizer and other authors reported ties with various sources, including Pfizer.

Source: Shi VY et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022 (Apr 16). Doi: 10.1016/j.jaad.2022.04.009